Insight Molecular Diagnostic (IMDX) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $5.8M

IMDX ranks #6680 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IMDX is a top-conviction position for Pura Vida Investments, LLC — at 7.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IMDX belongs to Broadwood Capital Inc, but the position matters far more to Pura Vida Investments, LLC, who has 7.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Family Office Research LLC has added to its IMDX position for two straight quarters, increasing it by $1.9M to reach $2.3M today.

IMDX is down 4% today, but institutions show net buying of $5.8M this quarter — a divergence between today's price move and the underlying institutional flow.

IMDX reported a net loss of $49.4M over the trailing twelve months.

• Not yet profitable — net loss of $49.4M over the trailing twelve months
• Revenue declined 60.8% year over year
• Net income improved year over year, from -$63.4M to -$49.4M
• Operating cash flow was negative, using $22.2M in cash
• Current ratio of 1.27x — below the conventional 1.5x liquidity buffer